Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 111

1.

Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol.

Song IH, Borland J, Chen S, Wajima T, Peppercorn AF, Piscitelli SC.

Ann Pharmacother. 2015 Jul;49(7):784-9. doi: 10.1177/1060028015580637. Epub 2015 Apr 10.

2.

Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.

Song I, Borland J, Chen S, Peppercorn A, Wajima T, Piscitelli SC.

Antimicrob Agents Chemother. 2014 Nov;58(11):6696-700. doi: 10.1128/AAC.03282-14. Epub 2014 Aug 25.

3.

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.

Song I, Borland J, Chen S, Guta P, Lou Y, Wilfret D, Wajima T, Savina P, Peppercorn A, Castellino S, Wagner D, Hosking L, Mosteller M, Rubio JP, Piscitelli SC.

Eur J Clin Pharmacol. 2014 Oct;70(10):1173-9. doi: 10.1007/s00228-014-1732-8. Epub 2014 Aug 23.

4.

ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.

Letendre SL, Mills AM, Tashima KT, Thomas DA, Min SS, Chen S, Song IH, Piscitelli SC; extended ING116070 study team.

Clin Infect Dis. 2014 Oct;59(7):1032-7. doi: 10.1093/cid/ciu477. Epub 2014 Jun 18.

5.

Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food.

Weller S, Chen S, Borland J, Savina P, Wynne B, Piscitelli SC.

J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):393-8. doi: 10.1097/QAI.0000000000000193.

PMID:
24798770
6.

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment.

Weller S, Borland J, Chen S, Johnson M, Savina P, Wynne B, Wajima T, Peppercorn AF, Piscitelli SC.

Eur J Clin Pharmacol. 2014 Jan;70(1):29-35. doi: 10.1007/s00228-013-1590-9. Epub 2013 Oct 6.

7.

Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls.

Song IH, Borland J, Savina PM, Chen S, Patel P, Wajima T, Peppercorn AF, Piscitelli SC.

Clin Pharmacol Drug Dev. 2013 Oct;2(4):342-348. Epub 2013 Aug 16.

8.

Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans.

Castellino S, Moss L, Wagner D, Borland J, Song I, Chen S, Lou Y, Min SS, Goljer I, Culp A, Piscitelli SC, Savina PM.

Antimicrob Agents Chemother. 2013 Aug;57(8):3536-46. doi: 10.1128/AAC.00292-13. Epub 2013 May 13.

9.

Effect of intravenous zanamivir on cardiac repolarization.

Lou Y, Gan J, Peppercorn A, Gould E, Weller S, Piscitelli SC, Patel P.

Pharmacotherapy. 2013 Jul;33(7):701-9. doi: 10.1002/phar.1261. Epub 2013 Apr 3.

PMID:
23553534
10.

A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects.

Koteff J, Borland J, Chen S, Song I, Peppercorn A, Koshiba T, Cannon C, Muster H, Piscitelli SC.

Br J Clin Pharmacol. 2013 Apr;75(4):990-6. doi: 10.1111/j.1365-2125.2012.04440.x.

11.

Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.

Chen S, Min SS, Peppercorn A, Borland J, Lou Y, Song I, Fujiwara T, Piscitelli SC.

Pharmacotherapy. 2012 Apr;32(4):333-9. doi: 10.1002/j.1875-9114.2012.01033.x. Epub 2012 Mar 15.

PMID:
22422361
12.

Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir.

Song I, Borland J, Chen S, Patel P, Wajima T, Peppercorn A, Piscitelli SC.

Antimicrob Agents Chemother. 2012 Mar;56(3):1627-9. doi: 10.1128/AAC.05739-11. Epub 2011 Dec 19.

13.

Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir.

Song I, Borland J, Min S, Lou Y, Chen S, Patel P, Wajima T, Piscitelli SC.

Antimicrob Agents Chemother. 2011 Jul;55(7):3517-21. doi: 10.1128/AAC.00073-11. Epub 2011 May 9.

14.

Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers.

Patel P, Song I, Borland J, Patel A, Lou Y, Chen S, Wajima T, Peppercorn A, Min SS, Piscitelli SC.

J Antimicrob Chemother. 2011 Jul;66(7):1567-72. doi: 10.1093/jac/dkr139. Epub 2011 Apr 14.

15.

Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.

Song I, Borland J, Chen S, Lou Y, Peppercorn A, Wajima T, Min S, Piscitelli SC.

Br J Clin Pharmacol. 2011 Jul;72(1):103-8. doi: 10.1111/j.1365-2125.2011.03947.x.

16.

Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects.

Song I, Min SS, Borland J, Lou Y, Chen S, Ishibashi T, Wajima T, Piscitelli SC.

J Acquir Immune Defic Syndr. 2010 Nov;55(3):365-7. doi: 10.1097/QAI.0b013e3181e67909.

PMID:
20585260
17.

The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants.

Song I, Min SS, Borland J, Lou Y, Chen S, Patel P, Ishibashi T, Piscitelli SC.

J Clin Pharmacol. 2011 Feb;51(2):237-42. doi: 10.1177/0091270010371113. Epub 2010 May 20.

PMID:
20489027
18.

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.

Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, Piscitelli SC.

Antimicrob Agents Chemother. 2010 Jan;54(1):254-8. doi: 10.1128/AAC.00842-09. Epub 2009 Nov 2.

19.

In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc.

Demarest JF, Sparks SS, Schell K, Shibayama S, McDanal CB, Fang L, Adkison KK, Shachoy-Clark A, Piscitelli SC.

J Clin Pharmacol. 2008 Oct;48(10):1179-88. doi: 10.1177/0091270008322178. Epub 2008 Aug 1.

PMID:
18676693
20.

Drug-cytokine interactions: mechanisms and clinical implications.

Reiss WG, Piscitelli SC.

BioDrugs. 1998 May;9(5):389-95.

PMID:
18020573
Items per page

Supplemental Content

Loading ...
Write to the Help Desk